Trials / Completed
CompletedNCT04285580
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
An Evaluation of the 24-Hour Intraocular Pressure(IOP)-Lowering Effect of Bimatoprost Sustained-Release(SR) in Participants With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimatoprost SR | Consists of 1 Bimatoprost SR administration in the study eye. |
| DRUG | LUMIGAN | Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study. |
Timeline
- Start date
- 2020-06-11
- Primary completion
- 2022-05-14
- Completion
- 2022-05-14
- First posted
- 2020-02-26
- Last updated
- 2023-06-08
- Results posted
- 2023-06-08
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04285580. Inclusion in this directory is not an endorsement.